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What’s already known about this topic?A
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 The infection caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), 
called COronaVIrus Disease-19 (COVID-19), has rapidly spread throughout the world becoming 
pandemic
 The heterogeneous spectrum of COVID-19-associated cutaneous manifestations is based on 
preliminary reports of different types of skin lesions, leading to a need for clarity 
What does this study add?
 A summary of the clinical and histological features of COVID-19-associated skin manifestations 
has been provided
 Six main clinical patterns can be identified: i) urticarial rash, ii) confluent 
erythematous/maculopapular/morbilliform rash, iii) papulovesicular exanthem, iv) chilblain-like 
acral pattern, v) livedo reticularis/racemosa-like pattern, vi) purpuric “vasculitic” pattern
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
SUMMARY
Background The infection caused by the recently identified SARS-CoV-2, called COronaVIrus Disease-19 
(COVID-19), has rapidly spread throughout the world. With the exponential increase of patients worldwide, 
the clinical spectrum of COVID-19 is being better defined and new symptoms are emerging. Numerous 
reports are documenting the occurrence of different cutaneous manifestations in COVID-19 patients.
Objectives To provide a brief overview of the COVID-19-associated cutaneous lesions.
Methods Literature search was performed in the PubMed, Scopus and Web of Science databases up to 30 
April 2020. This narrative review summarizes the available data regarding clinical and histological features 
of COVID-19-associated skin manifestations. 
Results Literature reports showed a great heterogeneity in COVID-19-associated cutaneous 
manifestations, as well as in their latency periods and associated extracutaneous symptoms. Pathogenic 
mechanisms are unknown, although the role of hyperactive immune response, complement activation and 
microvascular injury has been hypothesized. Based on our experience and the literature data, we 
subdivided the reported cutaneous lesions into six main clinical patterns: i) urticarial rash, ii) confluent 
erythematous/maculo-papular/morbilliform rash, iii) papulovesicular exanthem, iv) chilblain-like acral 
pattern, v) livedo reticularis/racemosa-like pattern, vi) purpuric “vasculitic” pattern. These six patterns can 
be merged into two main settings: the first one – inflammatory/exanthematous – including  the first three 
groups cited above and the second one including the vasculopathic/vasculitic lesions of the last three 
aforementioned groups.
Conclusions The possible presence of cutaneous findings leading to suspect COVID-19 puts 
dermatologists in a relevant position. Further studies are needed to delineate the diagnostic and prognostic 
value of such cutaneous manifestations.
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Background
A novel zoonotic enveloped RNA virus of the Coronaviridae family, that has been named “Severe Acute 
Respiratory Syndrome Coronavirus 2” (SARS-CoV-2), was identified in hospitalized patients with 
pneumonia  in Wuhan, China, in December 2019. The infection caused by the virus, called COronaVIrus 
Disease-19 (COVID-19), has rapidly spread throughout the world becoming pandemic in early March 
2020.1 
The clinical spectrum of COVID-19 is rather heterogeneous, ranging from unapparent or mild symptoms to 
critical fatal forms with respiratory failure, septic shock or multiorgan dysfunction. The clinical features at 
illness onset vary, but, over the disease course, patients mainly present with fever and respiratory 
symptoms. However, various signs and symptoms can occur, and, among the most common are fever, 
cough, fatigue, anorexia, shortness of breath, sputum production, myalgia, dyspnea, rhinorrhea, ageusia, 
anosmia,  pharyngodynia, headache and chills.1
With the exponential increase of infected patients worldwide, clinical characteristics of COVID-19 are being 
better defined and new symptoms are emerging.
In most of the early reports from China, cutaneous lesions were not generally included in the COVID-19 
clinical spectrum, apart from a few exceptions. For instance, Guan et al. described skin rash in 0.2% out of 
1,099 hospitalized patients, without specifying clinical patterns or further details.2 
Hoehl et al. observed a faint rash and minimal pharyngitis in one traveler returning from Wuhan to Germany 
in February 2020 who tested positive for SARS-CoV-2 by real-time reverse-transcription–polymerase-
chain-reaction (RT-PCR) of her throat swab.3 
Subsequently, a case of COVID-19 presenting with purpuric lesions mimicking dengue has been reported.4 
In Iran, the clinical findings of COVID-19 found in a 15-day-old neonate were fever, lethargy, respiratory 
distress without cough and cutaneous mottling.5 
Another report, which analyzed a series of 88 COVID-19 patients to describe the rate and type of skin 
lesions, drew the attention of the scientific community to the COVID-19-associated cutaneous 
manifestations.6 In all these patients, history of intake of any new drug in the previous 15 days was 
excluded. Cutaneous manifestations developed in 18 patients (20.4%) either at the onset of the disease 
(n=8) or after the admission (n=10) and consisted in erythematous rash (n=14), widespread urticaria (n=3) 
and chickenpox-like vesicles (n=1). The trunk was the most frequently affected area and itch was mild or 
absent. Skin lesions usually disappeared in a few days and did not show any apparent correlation with 
COVID-19 severity. 
Subsequently, various reports of skin manifestations in patients with COVID-19 have been published. It 
should be kept in mind that, at the beginning of this tremendous outbreak, the rapidly increasing rate of 
infected patients and the parallel multitude of severe and critical patients could have hampered systematic 
skin assessments. Therefore, cutaneous lesions are likely to have been underestimated for obvious 
reasons, including the paucity of dermatology consultations in this group of patients.7 Moreover, cutaneous 
lesions may have been neglected as their duration can be very short and local symptoms can be minimal or 
absent. The difficulty in determining the actual prevalence of COVID-19-associated skin manifestations has A
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also been linked to the fact that in some countries only patients with respiratory illness or requiring 
hospitalization are screened.8 
The aim of our article is to provide a brief overview of the COVID-19-associated cutaneous manifestations, 
accepting the preliminary nature of such data. 
Methods 
A literature search in the electronic databases PubMed, Scopus and Web of Science was conducted up to 
the 30th of April 2020, using the term “COVID-19” in combination with “skin”, “cutaneous manifestations”, 
“eruption”, “rash”, “exanthem”, “urticarial”, “chilblain”, “livedo”, and “purpura” in order to collect reports of 
skin manifestations described in patients with COVID-19. Given the limited number of papers, we included 
all the available clinical reports dealing with this very recent topic, most of which concerned individual cases 
or small case series. Articles were selected based on title and abstract. Full texts were then carefully read 
to evaluate the article content. Articles from the references cited in the retrieved papers were also manually 
searched as appropriate. 
Results
The present review was based upon the available literature to date, which consists predominantly of case 
reports and small case series, all graded by low quality evidence. Tables 1 and 2 contain a partial list of 
case reports,4,9-31 corresponding only to the description of single cases with detailed information. Such 
reports refer to patients with laboratory-confirmed COVID-19. In only one case,13 although multiple nucleic 
acid tests were negative, the infection was diagnosed on the basis of both chest computerized tomography 
(CT) scan findings and close contact with COVID-19 patients. Case series with more than three patients 
are not contained in these Tables and are described in depth throughout the text. The only report with 
higher quality evidence is that by Galván Casas et al. on a large cohort of patients,32 which allowed the 
authors to stratify COVID-19-related skin manifestations in five categories. Overall, the case reports 
suggest that skin lesions developed more often after the onset of COVID-19 symptoms, with a variable 
latency period. A simultaneous onset was sometimes noted, especially for fever. More rarely skin lesions 
occurred in the prodromal phase, shortly before the appearance of typical COVID-19 symptoms.9,27 Reports 
concerning asymptomatic subjects also exist. Different clinical patterns were described. 
Classification of COVID-19-associated cutaneous manifestations
A classification of cutaneous manifestations of COVID-19 has been proposed based on the results of a 
prospective nationwide consensus study in Spain using a representative sample of 375 cases.32 Five 
clinical patterns were recognized: i) acral areas of erythema with vesicles or pustules (pseudo-chilblains) 
(19%), ii) other vesicular eruptions (9%), iii) urticarial lesions (19%), iv) maculopapular eruptions (47%), v) 
livedo or necrosis (6%). Vesicular eruptions were found to appear early in the course of the disease (before 
other symptoms in 15% of cases), chilblain-like lesions frequently appear late over the disease course, 
whereas the remaining patterns tend to develop during the illness phase. Chilblain-like lesions also tend to A
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have a longer duration as compared to the other forms. A gradient of severity of COVID-19 could be 
observed ranging from less severe disease in acral lesions to most severe in the case of livedoid 
presentations.32 Nevertheless, transient livedoid eruptions have also been reported in the literature.28 
Based on our experience, review of the literature and the classification by Galván Casas et al. who studied 
a cohort of 375 Spanish patients,32 we subdivided the reported cutaneous lesions into six main clinical 
patterns: i) urticarial rash (Figure 1A),6,8-16, ii) confluent erythematous/maculopapular/morbilliform rash 
(Figure 1B),3,6,14,15,17-19,21-27 iii) papulovesicular exanthem (Figure 1D),6,20,33-35 iv) chilblain-like acral pattern 
(Figure 1C),8,29,30,33,36-41 v) livedo reticularis/racemosa-like pattern (Figure 1F),28,31 vi) purpuric “vasculitic” 
pattern (Figure 1E).31,33  Although livedo reticularis/racemosa and purpura could be included in the same 
setting, we decided to split them into two separate categories, keeping in mind the hypothesis that the 
former has a vasculopathic origin, while the latter admits a true vasculitic pathogenesis.   
For clarity of exposition, the six patterns were assigned to two broader categories: 
inflammatory/exanthematous eruptions, including  urticarial rash, confluent erythematous/maculo-
papular/morbilliform rash and papulovesicular exanthem (Table 1), and vasculopathic/vasculitic lesions, 
including chilblain-like acral pattern, livedo reticularis/racemosa-like pattern and purpuric “vasculitic” pattern 
(Table 2).
Exanthems and other inflammatory eruptions 
These encompass confluent erythematous, maculopapular, morbilliform and urticarial presentations, similar 
to non-specific rashes in the course of common viral infections. In the large cohort of 375 patients by 
Galván Casas et al., exanthems were the most commonly reported skin manifestations. In particular, 
maculopapular eruptions, urticarial lesions and vesicular eruptions accounted for 47%, 19% and 9% of all 
cutaneous manifestations, respectively.32  The main differential diagnoses in such presentations are 
cutaneous drug reactions. Itch was of variable intensity and sometimes absent. Urticarial and 
maculopapular exanthems have been suggested to appear simultaneously with systemic symptoms, to last 
approximately one week and to be associated with severe COVID-19.32  The possible presence of urticarial 
manifestations is unsurprising given that viral agents have been recognized as an important trigger of acute 
urticaria and urticaria-like rash, especially in children.42,43 Erythematous flexural lesions  were also noted,21 
as well as localized plaques on the heels,23 and a papulosquamous eruption, clinically reminiscent of 
pityriasis rosea.26 Gisondi et al. gave a brief mention of a diffuse papular eruption seen in a woman with 
COVID-19 febrile infection.44  Lesions resembling erythema multiforme have also been described.32
In some case reports (Table 1), the outcomes were not specified. When available, the data on the natural 
evolution generally indicated an overall short duration of skin involvement. 
Hedou et al. analyzed, in a prospective study, the incidence and types of cutaneous manifestations 
associated with COVID-19 in France.8 In total, 103 patients with confirmed infection (71 women) with a 
mean age of 47 yrs were evaluated. Among them, 76 were treated at home, 23 were admitted to 
conventional hospital wards and 4 to intensive care units. Only 5 (5%) presented with skin manifestations: 
erythematous rash (n=2) and urticaria (n=2), mainly located on the face and the upper body, and one case A
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of oral herpes simplex virus reactivation in an intubated patient. Cutaneous signs appeared during the 
prodromal phase in a patient with urticaria and during the illness in the remaining subjects. All eruptions 
were associated with itching and  disappeared within 6 days (median: 2 days). 
A further retrospective observational study recorded the occurrence of inflammatory lesions, usually a few 
days after the onset of COVID-19 systemic symptoms, in 7 patients, including exanthem (n=4), varicella-
like vesicles (n=2) and cold urticaria (n=1).33
An eruption worthy of separate comments is that characterized by vesicular or papulovesicular lesions 
resembling varicella (Table 1).6,20,34,35 
In the cohort observed by Galván Casas et al., vesicular lesions usually appeared in middle-aged patients, 
before systemic symptoms’ onset in 15% of cases and were associated with intermediate severity of 
COVID-19.32 
Eight Italian Dermatology Units collected clinical data on 22  patients with COVID-19 (16 males; median 
age: 60 years) and varicella-like lesions.34 In this study, which two authors of the present paper (A.V.M. and 
G.G) contributed to, the skin lesions usually appeared 3 days after systemic symptoms and disappeared 
after 8 days, without scarring. Systemic symptoms were fever (95.5%), followed by cough (73%), headache 
(50%), weakness (50%), coryza (45.5%), dyspnea (41%), and less frequently hyposmia, hypogeusia, 
pharyngodynia, diarrhoea, and myalgia. Death occurred in 3 patients. The authors reported that typical 
characteristics of the rash are frequent trunk involvement, scattered distribution and mild/absent pruritus 
speculating that this kind of eruption can be an almost specific COVID-19-associated cutaneous 
manifestation.34 The case of a  pediatric patient included in this series has been described in detail in 
another subsequently published report.20
Tammaro et al. presented data from their combined experience in Rome, Italy, and Barcelona, Spain, and 
focused on lesions similar to those found in infections caused by members of the Herpesviridae family.35 In 
particular, they described the case of a woman from Barcelona who developed numerous, isolated 
vesicular lesions on the back 8 days after the diagnosis of COVID-19. In the same paper, they  identified, 
among 130 COVID-19 patients hospitalized in Rome, two (1.5%) cases presenting with isolated 
erythematous-vesicular herpetiform lesions on their trunk accompanied by mild pruritus. 
Some cutaneous rashes encountered in association with COVID-19 were characterized by a petechial 
component,15,19,24,25 which may have been secondary to thrombocytopenia.4 These cases were not 
included in the purpuric “vasculitic” pattern of our classification because, in our opinion, petechial lesions in 
such circumstances were only an accompanying finding of inflammatory non-vasculitic eruptions which 
were predominantly characterized by macular or maculo-papular lesions. Petechial lesions could also 
represent a secondary phenomenon during the natural evolution of the exanthem, as described in a case in 
which a maculopapular rash became purpuric one week later.15 Erythematous-purpuric, maculopapular and 
petechial lesions with a tendency toward a flexural or periflexural distribution have also been reported.24,25
Vasculopathic/vasculitic lesionsA
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In a retrospective observational French study, seven patients presented with vascular lesions as follows: 
violaceous macules with “porcelain-like” appearance (n=1), livedo (n=1), non-necrotic purpura (n=1), 
necrotic purpura (n=1), eruptive cherry angiomas (n=1) chilblain-like lesions alone (n=1) and associated 
with Raynaud’s phenomenon (n=1).33 
Manifestations defined as petechiae, tiny bruises or livedoid eruptions have been linked to COVID-19, as 
reported by an article in a newsmagazine published by the Society of Hospital Medicine.45 Furthermore, it 
was speculated that these manifestations may be a result of small blood vessel occlusion whose 
pathogenic mechanisms (e.g., neurogenic, microthrombotic or immune complex-mediated) are as yet 
unknown.
Intriguingly, Magro et al. have documented the presence of thrombotic microvascular damage in the lung 
and/or skin of five critical COVID-19 patients.31 In three of these patients, purpuric/livedoid skin lesions 
(Table 2) characterized by a pauci-inflammatory microthrombotic vasculopathy were described (Table 3). 
Deposition of complement components within the skin and lung microvasculature (Table 3), with co-
localization of SARS-CoV-2-specific spike glycoproteins was detected. It was suggested that severe 
disease may induce a catastrophic generalized microvascular injury syndrome mediated by intense 
activation of the alternative and lectin complement pathways and an associated procoagulant state.31 
It is noteworthy to mention that Chinese authors reported the development of severe acro-ischemia in a few 
intensive care unit patients in Wuhan, manifesting as finger/toe cyanosis, skin blisters and dry gangrene, 
resulting from a hypercoagulable status or confirmed disseminated intravascular coagulation.46 
Alramthan et al. hypothesized that acral ischemia could be responsible for the acral red-purple perniosis-
like papules noted in two asymptomatic young women.29 Very mild processes of intravascular coagulation 
and microthrombosis have been implicated in the pathogenesis of transient localized livedo reticularis-like 
lesions.28 Biopsies were not taken in such cases because of the fleeting nature of skin lesions. 
Therefore, livedoid skin lesions might be mediated by an occlusive thrombotic microvasculopathy of 
variable magnitude. In many cases, these lesions are likely to be mild and transient. Nevertheless, Manalo 
et al., describing cases of transitory livedo reticularis-like patches (Table 2), declared that platelet count, 
coagulation studies, and fibrin degradation products assessments in these patients would be 
enlightening.28  In patients with severe COVID-19, vasculopathic lesions may be more pronounced and/or 
persistent, being the epiphenomenon of uncontrolled systemic microvascular damage or coagulopathy.
Interestingly, livedoid and necrotic lesions have been suggested to occur in elderly patients with severe 
systemic symptoms, likely representing the cutaneous manifestations associated with the highest rate of 
COVID-19-associated mortality.32 
In our classification, we distinguished a specific purpuric pattern that was defined as “vasculitic” in order to 
differentiate it from the petechial component of some exanthematous eruptions, as well as from livedo 
related to occlusive/microthrombotic vasculopathy. This pattern is likely to be extremely rare.31,33  In our 
experience, we observed a case of palpable purpura on the knees (Figure 1E) and another patient with 
purpuric and necrotic lesions of the lower legs, clinically resembling cutaneous leukocytoclastic vasculitis 
(unpublished data). In such cases, a vasculitic aetiology might be implicated, although histopathological A
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data were unavailable and further studies are required. Interestingly, among the three vasculopathic lesions 
in the setting of severe COVID-19 documented by Magro et al., the retiform purpura also showed prominent 
leukocytoclasia, suggesting the coexistence of a vasculitic process (Table 3).31
A peculiar cutaneous manifestation that is raising particular interest amongst dermatologists is represented 
by acral lesions resembling chilblains. 8,29,30,33,36-41   These atypical  presentations occurred in young 
patients confined at home during springtime, in the absence of cold exposure, comorbidities or other 
potential triggers. The rapid outbreak of perniosis-like lesions in parallel with COVID-19 pandemic reflected 
in the ever-growing number of reports of similar cases from various countries have led to hypothesize about 
a relationship between the disease and these clinical observations, although more data are needed to draw 
definite conclusions. In many cases, laboratory confirmation of the infection was not performed or gave 
negative results and/or complete information about testing was not available.
Nevertheless, various reports have suggested that such acro-ischemic chilblain-like lesions predominantly 
affect children and young people with an occasional history of systemic symptoms preceding cutaneous 
lesions.37,39,41 
The acral eruption was frequently characterized by erythematous-violaceous papules and macules, with 
possible bullous evolution, or digital swelling.41 Feet were more frequently affected than hands. Non-acral 
sites were rarely involved and sometimes showed lesions with a targetoid appearance.39,41 In some cases, 
this was likely to represent true virus-induced erythema multiforme, theoretically triggered by SARS-CoV-2 
(personal observation).  
In the study by Galván Casas et al., chilblain-like lesions affected younger patients, lasted for 
approximately 13 days, occurred  later in the course of COVID-19 and were  associated with less severe 
disease.32
In their series of 14 patients with acral perniosis-like lesions, some authors found no abnormalities of 
laboratory parameters (complete blood count, C-reactive protein, lactate dehydrogenase and D-dimer; 
serology for Epstein-Barr virus, Cytomegalovirus, Coxsackie and Parvovirus B19).41 RT-PCR test for 
SARS-CoV-2 from swab was performed in very few cases, with negative results. 
Fernandez-Nieto et al. retrospectively reviewed the data of 132 patients with acral lesions (mean age of 
19.9 years) between 5 March to 15 April 2020.37 Two main clinical patterns of acute acro-ischemic lesions 
were recognized, resembling chilblains and erythema multiforme, respectively. Of the total patients, 41% 
had close contact with COVID-19 patients and 14.4% were clinically diagnosed with COVID-19 (16 patients 
had skin lesions after a mean period of 9.2 days from the onset of COVID-19 symptoms, and 3 patients 
simultaneously). None of the patients had pneumonia or any other complication. In 11 patients, a RT-PCR 
assay was performed from a nasopharyngeal swab, after the appearance of skin lesions, and yielded 
positive results in only two patients. 
It has been speculated that chilblain-like lesions could represent late manifestations of COVID-19 in young 
healthy subjects.37,41 Future studies with serological examinations are necessary to corroborate this 
assumption. The lesions might result from a delayed immunological reaction against viral particles in A
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asymptomatic/pauci-symptomatic forms of COVID-9.33,41 An increased type I interferon reaction has also 
been  implicated.30,33.
Histopathological studies and other laboratory assessments on skin samples
Histopathological examination of lesional skin was performed in a limited number of cases (Table 3).
Inflammatory lesions generally showed non-specific features.10,15,16,22,25-27,34 The histopathological picture of 
exanthematous eruptions was usually compatible with viral exanthem. The clinico-pathological features 
found by Gianotti et al. were reminiscent of Grover’s disease in one patient and consistent with viral 
exanthem in the others.27 In the latter two cases peculiar findings were noted, with early dermal 
microthromboses in one and signs suggestive of lymphocytic vasculitis in the other.
Targetoid erythema multiforme-like lesions of the elbows, observed in patients with concomitant acral 
perniosis-like lesions, were characterized only by a mild superficial perivascular dermatitis.41  
Even fewer data are available on the histopathology of vasculopathic lesions.30,31,41
Chilblain-like lesions were characterized by lymphoid/lymphoplasmacytic infiltrate in the dermis, possibly 
extending to the hypodermis, and by a prevalent perivascular pattern.30,41 Signs of endothelial activation or 
plump endothelial cells in the venules surrounded by infiltrate were detected. 30,41
The purpuric/livedoid skin lesions observed by Magro et al. in three critical COVID-19 patients showed 
signs of thrombotic microvascular damage.31 In addition, histopathological examination of the livedoid 
lesions revealed no signs of inflammation in one case and mild perivascular lymphocytic infiltration in 
another. In contrast, the retiform purpura of a third patient showed neutrophilia with prominent 
leukocytoclasia along with  necrotic changes in the epidermis and adnexa. Immunohistochemical 
assessment demonstrated  significant deposition of complement components within the skin 
microvasculature (Table 3). In two cases, a biopsy taken from the normal-appearing skin showed 
microvascular deposits of C5b-9 throughout the dermis.
Direct immunofluorescence studies were performed only in a case of erythematous-oedematous figurate 
plaques16  and in a patient with chilblain-like acral lesions30, providing negative results in both cases.
RT-PCR for SARS-CoV-2 was very rarely performed on lesional skin samples, and again negative results 
were obtained.22,26
Conclusions
Different cutaneous manifestations have been described in the setting of COVID-19. Although their 
pathogenic mechanisms are still unclear, hyperactive immune response, complement activation and 
microvascular injury have been implicated. The possible relationship between skin manifestations and 
COVID-19 is an important aspect that deserves great attention and efforts in order to improve our 
understanding of such phenomena. On the other hand, the contributing role of other infectious agents, 
patient comorbidities, immune status, concurrent treatments and other still undefined factors remains 
speculative.A
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The presence of cutaneous findings that can lead to suspect COVID-19 and identify potentially contagious 
cases with indolent course puts dermatologists in a relevant position.  Furthermore, the role of  COVID-19-
associated skin manifestations as prognostic markers needs to be further deepened.
However, literature reports indicated a great heterogeneity in cutaneous manifestations, their latency 
periods and associated extracutaneous symptoms. Moreover, difficulties are increased by the possible 
occurrence of skin  lesions in paucisymptomatic or asymptomatic subjects. Wide use of reliable serologic 
assays can have an important value. Moreover, in future studies it would be useful to assess the viral load 
in different timepoints,47 and to detect viral RNA or particles within lesional skin.
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Table 1 Case reports of exanthems and inflammatory eruptions in COVID-19 patients 
Authors Sex/Age
Relevant history 
(if present)
Clinical features of skin lesions Respiratory and other relevant symptoms/signs in relation 
to the onset of skin lesions 
Treatments for 
COVID-19 
Outcome of 
skin lesions
Henry et al.9 F (27 yrs) Pruritic urticarial rash Prodromal odynophagia; concomitant arthralgia; chills, chest 
pain and fever (up to 39,2°C) 48 hours after the onset of skin 
lesions
Paracetamol Slow 
improvement 
(n.s.)
Fernandez-
Nieto et al.10
F (32 yrs) Urticarial rash COVID-19 symptoms (n.s.) started 6 days before Hydroxychloroquine 
and azithromycin  
Improvement 
after 5 days
Quintana-
Castanedo et 
al.11
M (61 yrs) Mildly itchy urticarial exanthem Concomitant body temperature of 37.3ºC.
No symptoms (RT-PCR performed due to epidemiological link)
None Disappearance 
after 7 days
M (71 yrs) - Obesity; DB; 
AH; OSAHS; RF on 
dialysis; previous stroke; 
hypercholesterolemia
Urticarial rash Concomitant fever and general weakness
Progressive deterioration up to respiratory failure and death
n.s. Improvement Van Damme
et al.12
F (39 yrs) Pruritic generalized urticarial rash  Concomitant fever (38.3°C) with chills, myalgia, headache, 
then rhinorrhea, mild dry cough, dyspnea; later anosmia  and 
ageusia 
n.s. Gradual 
improvement
Lu et al.13 One case (n.s.) Urticarial rash Mild dry cough started a few days before Ribavirin and 
interferon
n.s.
M (6 yrs) Erythematous, nonpruritic 
maculopapular exanthem
Low-grade fever 2 days before None Disappearance 
after 5 days
Morey-Olivé et 
al.14
F (2 months) Urticaria-like exanthem Concomitant low-fever None Disappearance 
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after 5 days
M (60 yrs) - mitral 
valve replacement,
paroxysmal atrial 
fibrillation, depression
Asymptomatic erythematous 
maculopapular rash on the back, 
flanks, groin and upper thighs 
becoming purpuric one week later
Low-grade fever (38°C), myalgias, fatigue, mild cough 3 days 
before
None n.s.Rivera-Oyola et 
al.15l
F (60 yrs) Generalized, pruritic urticarial rash  Low-grade fever (38.2°C), myalgias, fatigue, mild cough, 
gastrointestinal symptoms started 9 days before
None Disappearance 
after a few days
Amatore et al.16 M (39 yrs) Nonpruritic erythematous, 
edematous, annular and circinate 
fixed plaques on upper limbs, 
chest, neck, abdomen, palms
Concomitant fever (39°C)
Pulmonary findings suggestive of COVID-19 on CT scan 
without respiratory symptoms
Hydroxychloroquine Disappearance 
after 8 days
Najarian17 M (58 yrs) Pruritic diffuse morbilliform rash Cough, pain in legs/hands shortly before; no fever Azithromycin and 
benzonatate 
Disappearance 
after a few days 
Hunt et al.18 M (20 yrs) Nonpruritic diffuse, morbilliform 
rash, sparing the face
Concomitant fever; initial signs suggestive of an upper 
respiratory infection, with pneumonia diagnosed 6 days later
n.s. n.s.
Avellana 
Moreno et al.19
F (32 yrs) Generalized, pruritic morbilliform 
rash (petechial and erythematous 
maculopapular lesions and a scaly 
reaction on the 4th day)
Fever, myalgia, asthenia 6 days before; later cough, diarrhea Paracetamol Disappearance 
after the 4th day 
(n.s.)
Genovese et 
al.20
F (8 yrs) Asymptomatic papulovesicular
(varicella-like) rash on the trunk
Mild cough started 3 days before 
Mild transient thrombocytopenia 
Mild fever 2 days after the onset of skin lesions
None Disappearance 
after 7 days
Mahé et al.21 F (64 yrs) – DM Erythematous symmetrical flexural 
rash (antecubital folds, then trunk 
and axillary folds)
Prodromal fever (up to 40°C) and asthenia (4 days before); 
concomitant cough with confirmation of interstitial pneumonia 
and persistent fever
Paracetamol from 
fever onset until day 
16
Disappearance 
after 5 days  
(day 9 of the 
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disease)
Ahouach et 
al.22
F (57 yrs) Diffuse erythematous blanching 
maculopapular lesions, with 
symptoms (burning sensation) 
only on the palms 
Fever (39 °C) 2 days before
Concomitant dry cough 
Typical thorax CT scan findings
Paracetamol Disappearance 
within 9 days
Estébanez et 
al.23
F (28 yrs) Pruritic erythematous-yellowish 
papules on both heels (13 days 
after being tested), becoming  
plaques 3 days later
Initially, dry cough, nasal congestion, fatigue, myalgias and 
arthralgias without fever, then diarrhea, ageusia and anosmia 
Paracetamol for a few 
days
n.s.
Jimenez-Cauhe
et al.24
F (84 yrs) - AH; 
dyslipidemia
Flexural erythematous-purpuric  
macules, mildly pruriginous, 
mainly in the peri-axillary area (on 
the 3rd hospital day)
Respiratory symptoms requiring hospitalization 11 days before Hydroxychloroquine 
and lopinavir/ritonavir 
n.s.
Joob et al.4 One case (n.s.) Petechial rash, misdiagnosed as 
dengue
Presence of thrombocytopenia 
Further presentation of respiratory problems requiring referral 
to a tertiary medical center (other information not given)
n.s. n.s.
Diaz-
Guimaraens et 
al.25
M (48 yrs) – AH Mildly pruritic, maculo-papular and 
petechial rash, with periflexural 
distribution
Fever (up to 39 °C) 3 days before, along with chest pain and 
shortness of breath.
Hospitalization for pneumonia
Hydroxychloroquine, 
lopinavir-ritonavir 
and azithromycin 
Disappearance 
after 5 days  
Sanchez et al.26 n.s (elderly) – AH; DM; 
peripheral artery 
disease; RF
Digitate papulosquamous eruption 
on the trunk, upper limbs and 
thighs  (on the 2nd hospital day)
Fever, fatigue, dyspnea one week before Hospitalization for 
acute respiratory distress. Death
n.s. Disappearance 
within 7 days
Gianotti et al.27 F (59 yrs) Widespread erythematous 
macules on arms, trunk and lower 
limbs (on the 3rd hospital day)
Bilateral interstitial pneumonia requiring hospitalization Lopinavir/ritonavir, 
heparin
and levofloxacin
Improvement 
within 5 days
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F (89 yrs) Erythematous papular exanthem 
on the trunk and arms (on 
admission)
Fever and cough started 7 days before Ceftriaxone and 
azithromycin
Improvement 
after 8 days
M (57 yrs) Widespread pruritic eruption of 
erythematous macules and 
papules
Fever, headache, cough and arthralgia two days after the 
onset of the rash
Levofloxacin and 
hydroxychloroquine
Improvement 
after 10 days
AH= Arterial hypertension; CT= computed tomography; DM= diabetes mellitus; F= female; M= male; n.s.= not specified; OSAHS= obstructive sleep apnea-hypopnea syndrome; RF= 
renal failure; RT-PCR= real-time reverse-transcription–polymerase-chain-reaction; SARS-CoV-2= severe acute respiratory syndrome coronavirus 2
Table 2  Case reports of vasculopathic skin lesions in COVID-19 patients 
Authors Sex/Age
Relevant history (if present)
Clinical features of skin lesions Respiratory symptoms and other relevant findings Treatments for 
COVID-19
M (67 yrs) Non-pruritic LR-like livedoid patch on the 
right thigh  
Disappearance after 19 hours
Low-grade fever, nasal congestion, post-nasal drip, cough, 
shortness of breath 7 days before; concomitant weakness 
and transient hematuria
n.s. Manalo et 
al.28
F (47 yrs)
CD; HT; past portal vein 
thrombosis
Asymptomatic LR-like rash on right leg 
immediately after sunlight exposure (10 
days after testing positive) 
Disappearance after 20 minutes
Previous appearance of mild headache, sinus pressure, 
anosmia and fever  (up to 37.9°C) 
n.s.
F (27 yrs) No symptoms -Alramthan 
et al.29 F (35 yrs)
Red-purple papules on the dorsal aspect 
of fingers bilaterally in both cases (also 
subungual erythema in the right thumb in 
the 2nd case)
No symptoms -
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Kolivras et 
al.30
M (23 yrs) 
Psoriasis (secukinumab 
stopped one month before)
Violaceous, infiltrated, and painful
plaques on the toes and lateral aspects 
of the feet
Low-grade fever (37.7°C) and dry cough.3 days before -
M (32 yrs) 
OASA; anabolic steroid use 
(current use of testosterone)
After 4 days on ventilator support, 
retiform purpura with surrounding
inflammation on buttocks
Fever, cough, then dyspnea up to acute respiratory failure 
(elevated D-dimer and INR; normal PTT and platelet count)
Mechanical 
ventilation 
Hydroxychloroquine 
Azithromycin
Remdesivir
F (66 yrs) On hospital day 11, dusky livedoid 
patches on palms and soles bilaterally
Fever, cough, diarrhea, chest pain for 9 days.
Hypoxemia on admission.
Comatose state after further 3 days
(low platelet count; high D-dimer; normal INR and PTT)
Hydroxychloroquine
Enoxaparin
Intubation
Renal replacement
Magro et 
al.31
F (40 yrs) Mildly purpuric reticulated eruptions on 
the chest, legs and arms (livedo 
racemosa)
Dry cough, fever, myalgias, diarrhea for 2 weeks and 
progressive dyspnea. Then, severe reduction of left 
ventricular function, respiratory failure, shock 
(elevated D-dimer and INR; normal platelet count and PTT)
Intubation
CD= celiac disease; F= female;  HT= Hashimoto’s thyroiditis; INR= international normalized ratio; LR= livedo reticularis; M= male; n.s.= not specified; OASA= obesity-associated 
sleep apnea; PTT= Partial Thromboplastin Time.
Table 3 Histopathological features of cutaneous manifestations found in patients with COVID-19
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Authors Clinical form Main histopathological features
Fernandez-
Nieto et al.10 
Urticarial rash Upper dermal edema 
Perivascular infiltrate of lymphocytes and some eosinophils
Amatore et 
al.16
Urticarial figurate 
lesions
Lichenoid and vacuolar interface dermatitis
Mild spongiosis and dyskeratotic basal keratinocytes 
Papillary dermal edema with superficial perivascular lymphocytic infiltrate and occasional neutrophils 
Ahouach et 
al.22
Erythematous 
maculopapular rash
Slight spongiosis and basal cell vacuolation 
Mild perivascular lymphocytic infiltrate
Erythematous 
eruption
Superficial perivascular dermatitis with slight lymphocytic exocytosis
Presence of a small thrombus in a vessel in the mid dermis
Swollen thrombosed vessels with neutrophils, eosinophils and nuclear debris patchy distributed in the dermis
Erythematous-
papular exanthem 
Superficial and deep perivascular dermatitis 
Cuffs of lymphocytes surrounding blood vessels in a vasculitic pattern 
In the mid dermis extravasated red blood cells from damaged vessels
Gianotti et 
al.27
Erythematous-
papular eruption 
Superficial perivascular vesicular dermatitis, with features reminiscent of Grover’s disease
Focal acantholytic suprabasal clefts
Dyskeratotic and ballooning herpes-like keratinocytes 
Presence of a nest of Langerhans cells within the epidermis 
Patchy band-like infiltration  with occasional necrotic keratinocytes and minimal lymphocytic satellitosis
In the dermis, swollen vessels, with dense lymphocyte infiltration, mixed with rare eosinophils
Sanchez et 
al.26
Papulosquamous 
eruption 
Focal parakeratosis in the epidermis 
Mild spongiosis, with a few spongiotic vesicles containing lymphocytes and Langerhans cells
Papillary dermal edema  with moderate superficial lymphohistiocytic infiltrate 
Diaz-
Guimaraens 
et al.25
Maculo-papular and 
petechial rash 
Focal parakeratosis and isolated dyskeratotic cells
Focal papillary dermal edema and superficial perivascular lymphocytic infiltrate
Extravasated red cells
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No signs of thrombotic vasculopathy
Rivera-Oyola 
et al.15l 
Erythematous 
maculo-papular rash 
with purpuric 
evolution
Mild perivascular infiltrate of predominantly mononuclear cells in the superficial dermis
Scattered foci of hydropic changes in the epidermis and slight spongiosis 
Minimal acanthosis and focal parakeratosis
Marzano et 
al.34
Varicella-like lesions 
(n=7)
Features compatible with viral exanthem
Targetoid non-acral 
lesions (n=2)
Mild superficial perivascular dermatitisRecalcati et 
al.41
Perniosis-like lesions 
on the fingers (n=2) 
Diffuse dense dermal-hypodermal lymphoid infiltrate with a prevalent perivascular pattern
Signs of endothelial activation 
Kolivras et 
al.30
Chilblain-like lesions Epidermal basal vacuolar alteration and scattered necrotic keratinocytes
Superficial and deep lichenoid, perivascular and perieccrine infiltrate of lymphocytes and occasional plasma cells
Presence of some nuclear debris without neutrophils
Plump endothelial cells in the venules surrounded by the lymphoplasmacytic infiltrate 
Absence of intraluminal thrombi or fibrin within venule walls
Retiform purpura Thrombogenic vasculopathy
Extensive necrosis of the epidermis and adnexal structures
Interstitial and perivascular neutrophilia with prominent leukocytoclasia 
(IHC: extensive deposits of C5b-9 within the microvasculature)
Palmoplantar 
livedoid patches 
Superficial vascular ectasia and occlusive arterial thrombus within the deeper dermis 
Absence of inflammation 
(IHC: extensive vascular deposits of C5b-9, C3d, and C4d throughout the dermis, with marked deposition in an 
occluded artery)
Magro et al.31
Livedo racemosa Modest perivascular lymphocytic infiltrate in the superficial dermis along with deeper seated small thrombi within 
rare venules of the deep dermis, in the absence of a clear vasculitis 
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(IHC: significant vascular deposits of C5b-9 and C4d)
IHC= immunohistochemical assessment
Figure 1. COVID-19-associated cutaneous manifestations. A, Urticarial rash. B, Combination of confluent erythematous rash on the chest with petechial 
lesions on the abdomen and upper extremities. C, Acral chilblain-like lesions on the foot . D, Vesicular exanthem. E, Palpable purpura on the knees. F, Livedo 
racemosa-like lesions on the thighs. All the photographs belong to the authors’ own collection. 
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